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• DreamPad™ is deemed acceptable & feasible for use by people living with dementia. 
• Evidence of Dreampad™ effect on sleep, wandering & agitation yet to be established. 
• Use of wearable actigraph in research for people with dementia remains challenging. 
 2 
A feasibility study of Dreampad™ on sleep, wandering and agitated behaviors in people 
living with dementia. 
Running title: Technology to improve sleep, wandering & agitation in PWD 
 
Abstract 
Background: People living with dementia experience fragmented sleep-wake cycles. Their 
sleep patterns are shorter, lighter and easily disturbed. Disturbed sleep can lead to behaviors 
such as wandering and agitation, placing the person at risk of harm and increasing burden of 
care and pharmaceutical treatment costs.  
Methods: This feasibility study examined the acceptability, efficacy and implementation and 
practicality of Dreampad™, a sleeping device, on sleep disturbance and wandering and agitated 
behaviors. Four nursing home residents (2 males and 2 females; mean age=89.8 years 
(SD=7.2); mean MMSE scores=9.3 (SD=8.7)) used Dreampad™ daily over 4-weeks when they 
slept. Agitation was assessed before and after the intervention using the Cohen-Mansfield 
Agitation Inventory - Short Form. Wandering and sleeping patterns were assessed using a 
wearable actigraphy device over 24 hours at baseline and every week during the intervention.  
Results: Dreampad™ was deemed acceptable and feasible for use with people living with 
dementia by family and care staff. No support for Dreampad™ in improving sleep or behaviors 
of agitation and wandering was found. Challenges in using the wearable actigraphy device are 
reported.  
Conclusion: Attention is needed to ensure consistent use of Dreampad™ by people living with 
dementia and their wear adherence of the actigraphy device. Further rigorous research is 
warranted to address reported limitations in intervention and data collection processes and 
measurements and can be guided by the study outcomes.  
Keywords: Dreampad™, technology, sleep, agitation, wandering, people living with dementia 
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1. Introduction 
Globally, an estimated 50 million people live with dementia, and this number is expected to 
increase to 131.5 million by 2050 (1). Dementia is one of the top ten leading contributors to 
disability in people aged 60 years and over, with a rising worldwide cost of US$818 billion in 
2015 to an estimated US$2 trillion by 2030 (2). In Australia, prevalence estimates indicate that 
over 60 per cent of the current population residing in long-term care facilities have dementia 
(3), and this number is predicted to increase in the coming years. Of these, over one half will 
display behavioral and psychological symptoms of dementia (BPSD) (4). 
 
Dementia is a clinical syndrome characterized by deteriorations in cognitive, neuropsychiatric 
and functional skills. Sleep disturbances are common in this population (5). There are well-
recognized reports of changes to the sleeping patterns of people living with dementia over and 
above the typical age-related sleep disturbances (6-8). Besides experiencing sleep which is 
shorter, lighter and more easily disturbed (6), people living with dementia also have more 
fragmented sleep-wake cycles, with more sleep occurring during the day and less at night (9), 
than healthy older people. 
 
Further to alterations in the circadian regulation of sleep and changes in the duration and 
maintenance of sleep, dementia is linked to a sleep-wake disorder emerging in the late 
afternoon or evening and is known as Sundowning. The severity of cognitive impairment is an 
important predisposing factor in the development of the symptoms of Sundowning (10). 
Sundowning in people living with dementia is defined as increased arousal or impairment 
characterized by disruptive behaviors such as wandering, agitation, incoherent vocalisation, 
confusion and disorientation in the late afternoon, evening or at night (11-13). Around 10% to 
25% of people living in aged care facilities exhibit signs of Sundowning (14). Furthermore, 
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dementia-related wandering and agitation are common yet distinct behaviors where wandering 
is considered as a “locomotion behavior having a frequent, repetitive, temporally-disordered 
and/or spatially-disoriented nature that is manifested in lapping, random and/or pacing 
patterns, some of which are associated with eloping, eloping attempts or getting lost unless 
accompanied” (15). In contrast, agitation is connected to feelings of tension and unsettledness 
conveyed via actions and movements but not limited to locomotion (15). These behaviors (i.e. 
Sundowning, wandering and agitation) are difficult to manage and increase the burden of care.  
 
Sleep disturbances have been identified as significant predictors of wandering behaviors (16) 
and instrumental in the rapid decline in cognitive functioning (17). In more severe cases of a 
fragmented sleep-wake cycle, people living with dementia have been reported to demonstrate 
social dysfunction as well as agitated and wandering behaviors as a standard part of their daily 
routine (18). In residential aged care facilities (RACFs), wandering places the person at risk 
for falls, increased exposure to environmental hazards such as wet floors, and harmful 
interactions with other residents. Sustained injuries can occur as a result of the provocation of 
other residents when the person wanders into others ‘personal space’ (19). 
 
Effective strategies to improve sleep in people living with dementia and particularly in those 
who are living in RACFs are needed. However, to date, there have been limited options 
available apart from pharmacological treatment. A literature review of sleep in residential aged 
care reported the limited benefits and concerning side effects in the pharmacological treatment 
of sleep disturbances (20). The review also indicated that although there is promising support 
for psychosocial interventions such as exercise, music therapy, light therapy, aromatherapy, 
cognitive behavioral therapy, acupuncture, yi-gan san, valerian, melatonin and ramelteon; 
outcomes and protocols have been inconsistent. Further research is required to identify optimal 
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treatments with feasibility and pilot testing, followed by rigorous testing to verify beneficial 
outcomes. 
 
Insert Figure 1. 
1.1 Dreampad™ 
Dreampad™ is a sleeping device in the form of a customised, removable, washable, quilted 
cover, which is placed over a pillow that connects to a music player (e.g. MP3 or smart device) 
directly or via Bluetooth. Developed in the United States of America, Dreampad™ delivers 
bone-conducted, low frequency-rich music through a gentle, calming vibration, which is 
carried internally by the cranium to the cochlea, that only the user can hear (refer to Figure 1). 
Human bones are natural conductors. When a person speaks, the vibration caused by his/her 
voice is carried by the bone to the inner ear. According to its developer (21), the Intrasound 
Technology™, embedded in Dreampad™, replicates this natural process by using 
electromechanical transducers to convert the properties of sound to gentle vibration that is 
audible only to the user. When a user’s head is in contact with Dreampad™, the vibration is 
carried to the middle and inner ear, which is the home of the cochlear/vestibular apparatus, 
which governs one’s ability to hear and filter out unwanted noise (related to auditory 
hypersensitivity). It is also an area that is connected to the parasympathetic branch of the 
nervous system, which facilitates a relaxation response through the vagus nerve. It is believed 
that physiological and cognitive processes are slowed down due to an increase in the 
parasympathetic nervous system activity induced by the vibrations (22). Hence, the use of 
Dreampad™ brings about a relaxation response from the body and mind which has been aptly 
described by the developer as a “massage to the nervous system’” to reduce stress, improve 
sleep (i.e. falling and staying asleep), and decrease audio hypersensitivity (21).  
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Users can listen to their preferred music; however, Dreampad™ recommends and provides a 
list of pre-selected music designed to emphasize frequencies of the auditory spectrum most 
conducive for relaxation and sleep. Dreampad™ music, which consists of nature sounds, 
instrumental and classical music with no vocals, is available either on a pre-loaded MP3 player 
or can be downloaded via the Dreampad™ sleep supplication on both android and apple 
platforms (21). While sound volume can be adjusted to the preference of users, Dreampad™ 
works differently to conventional speakers in that music travels through vibrational 
soundwaves, which resonate through the pillow, rather than airwaves. 
 
The limited research to date on the use of Dreampad™ has shown promising results (23) in 
improving sleep, behaviors, attention and quality of life in children with Attention Deficit 
Hyperactivity Disorder (ADHD) and the device was deemed acceptable and feasible for use by 
parents (24, 25). Dreampad™ was also found to reduce night-time awakening when compared 
to other sleep interventions such as meditation and sleep hygiene in people aged 25 to 65 year 
with self-reported poor sleep (26) and improve sleep quality in people with insomnia (27). 
However, there is no published study examining the use of Dreampad™ with people living 
with dementia. This project expands existing research on Dreampad™ and aims to determine 
the feasibility of using Dreampad™ to improve sleep, wandering and agitated behaviors in 
people living with dementia in RACFs. 
 
2. Materials and Methods 
2.1 Design & Setting 
A mixed-methods approach involving (a) data on sleeping patterns, wandering and agitated 
behaviors of people living with dementia, assessed before and after the Dreampad™ 
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intervention, as well as (b) post-intervention semi-structured interviews were used to determine 
the feasibility of using Dreampad™.  
 
Residential aged care facilities were eligible for inclusion if they were Australian government 
approved and accredited within a 60kms radius of the Brisbane central business district and 
provided care for people living with dementia. The two RACFs from the same aged care 
organization where this study took place were known to the researchers, and their care director 
expressed an interest to be involved in this study. Ethics approval for this study was received 




Residents who had: (a) no auditory impairments; (b) a diagnosis of dementia or a Mini-Mental 
State Examination (MMSE) score of 24 or less that was indicative of mild dementia (28); and 
(c) a recent history reported by care staff and/or family of sleep disturbance and wandering and 
agitated behaviors were recruited for this study. A senior staff member from each participating 
RACF assisted with recruitment by identifying potential participants, who met the inclusion 
criteria and providing them and their families with informed consent materials. When interest 
to participate in the study was indicated, a member of the research team then met with the 
person with dementia and his/her family to discuss the study, answer questions and demonstrate 
the use of Dreampad™ before seeking their signed informed consent.  
 
With four available Dreampad™, only a total of four residents aged 65 years and over (i.e. 
three from one RACF and one from a second RACF) were identified, approached and 
successfully recruited while they continued their routine pharmaceutical treatments throughout 
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the study. All participants, if capable as indicated by the RACFs, or their next-of-kin provided 
written informed consent at the time of enrolment into the study. A family member who visited 
regularly or a care staff member who had regular contact for each participant was also recruited. 
Family member and care staff provided written, informed consent for their participation.  
 
2.3 Intervention 
Participants were asked to use Dreampad™ daily over a 4-week intervention period when they 
slept during the day and at night. Previous studies examining the effect of Dreampad™ on 
sleep had an intervention period ranging from 2 to 4 weeks (24, 26, 27). However, as no study 
has been conducted with people living with dementia, a conservative approach of a 4-week 
intervention was adopted in this study to ensure the feasibility of using Dreampad™ to improve 
sleep, wandering and agitated behaviors were adequately assessed.  
 
Care staff placed Dreampad™ over each participants’ usual pillow together with a protective 
waterproof pillowcase over it that was washed and replaced with a substitute backup when 
soiled. Regardless of when sleep occurs, the same playlist of five Dreampad™ music, set on a 
repeating mode for the recommended 2 hours of playing, was delivered via an MP3 device by 
care staff while participants slept. If participants indicated their refusal to use Dreampad™ for 
any reason (e.g. annoyance with the music) when sleeping, the MP3 device was removed with 
an attempt to use it again at the participants’ next sleep. Besides facilitating the use of 
Dreampad™ by care staff that included the completion of an intervention checklist, a research 
assistant visited participating RACFs weekly to check and encourage usage as well as to 
address any usage issues raised by participants and care staff.  
 
2.4 Data Collection 
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Using an adapted version of the Bowen Feasibility Framework (29), Dreampad™ was 
examined in terms of its acceptability, efficacy as well as implementation and practicality as 
reflected in Table 1. Different sources of data were used to present triangulated information to 
enhance the credibility and robustness of findings (30).   
Insert Table 1.  
 
2.4.1 Demographic, Sleep, Wandering & Agitation 
Participants’ demographic data, which included age, gender, type of dementia and length of 
time in residential care, were collected at baseline. 
 
Insert Figure 2. 
An actigraph called SenseWear® Professional 8.0 activity armband (Temple Healthcare, 
BodyMedia, Inc.) (refer to Figure 2) was placed every Tuesday on each participant for one 24-
hour period at Week 0 (i.e. baseline – one week before the start of the Dreampad™ 
intervention) and once a week during each of the 4-week intervention periods totalling 120 
hours per participant. Participants were asked to wear the armband continuously for 24 hours, 
removing only for bathing. The armband was placed and removed from participants by a 
research assistant. However, care staff were also trained on how to place the armband on 
participants if it was removed. SenseWear® is a slim, nonintrusive armband. Several sensors 
are incorporated into the device which is worn on the back of the upper right arm over the 
tricep muscle and held in place by a Velcro armband. Accelerometry is measured using a two-
axis micro-electronic mechanical sensor, and the device has a built-in algorithm that can 
identify the physical activity, sleep and wakefulness based on arm movement (31). 
SenseWear® was used to assess wandering (i.e. step count) as well as sleep type (i.e. non-
Rapid Eye Movement [REM] sleep), deep (i.e. from non-REM to REM sleep), and very deep 
 10 
sleep (i.e. REM sleep)) and duration of participants. SenseWear® has been used in other studies 
of similar duration (i.e. 24 hours) with people living with dementia (32, 33).  
 
Care staff were asked to review each participant’s state of agitation over the previous fortnight 
using the Cohen-Mansfield Agitation Inventory-Short Form (CMAI-SF) (34) before (i.e. 
baseline) and after the end of the intervention. The CMAI-SF has established reliability and 
validity and uses a 5-point scale to indicate participants displayed agitated behaviors during 
the previous 2 weeks. A total score ranges from 14 to 70, with higher scores indicating greater 
levels of agitation. 
 
2.4.2 Interviews 
Semi-structured interviews were conducted at the facility within four days of the end of the 
intervention to seek care staff and family’s perceptions of the feasibility of Dreampad™ and 
its effect on participant’s sleeping patterns and the behaviors of wandering and agitation. 
Interview questions included: “Tell me your initial perceptions of the Dreampad™? Did these 
perceptions change at any time after residents started using the Dreampad™?”; “Did you 
notice any improvement or decline in residents’ sleep patterns and behaviors of wandering or 
agitation?”; “What benefits/limitations do you see of the Dreampad™? Why? Tell me more 
about that.”; “Do you have any concerns about the use of the Dreampad™? What are these 
concerns?”; “The Dreampad™ costs $530. What are your perceptions about the cost of the 
Dreampad™? “; and “Should facilities purchase Dreampad™? Could families be asked to 
contribute to the cost?”. All interviews were digitally recorded and transcribed before analysis. 
 
2.4.3 Intervention Checklist & Research Team Observation Notes 
 11 
Each evening during the 4-week intervention period, care staff were also asked to indicate on 
a checklist whether the participant has gone to bed using the Dreampad™ and to note any sleep-
related behaviors or concerns and the known or possible reasons for these issues (refer to Table 
2). A record of technical difficulties (i.e. type and frequency) and the steps taken to address 
them, if any, were kept. Also, observation notes on issues that may have impacted on the 
intervention and influenced the experience of participants and perceptions of family and staff 
were recorded. 
Insert Table 2. 
 
2.5 Data Analysis 
All data collected were analyzed using IBM SPSS Statistics for Windows Version 24.0 
(Armonk, NY: IBM Corp.). Besides descriptive statistics, paired sample t-tests were conducted 
to determine pre- and post- intervention outcomes with a significant alpha level set at p<.05. 
Thematic analysis was used to explore the qualitative interview to reveal key issues of 
importance (35). The process of analysis involved two members of the research team first 
reading the interview transcripts and conducting a line-by-line analysis to compare with and 
between transcripts. Similar and dissimilar key issues were identified, followed by a clustering 
of key issues. Finally, transcripts were re-read to check the credibility of key issues (35).  
 
3. Results 
Residents, family and care staff participants served as the main identifiers of feasibility. A 
convenience sample of care staff (n=3; all female enrolled/registered nurses) engaged in the 
care of the participants and a family member (n=1; wife) who regularly visited her care recipient 
were interviewed, which ranged from only 6.0 to 12.1 minutes (M=8.5), while four residents 
participated in the use of Dreampad™. As reflected in Table 3, the mean age of the four 
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participants (i.e. 2 males and 2 females) was 89.8 years (SD=7.2) with an average MMSE score 
of 9.3 (SD=8.7). Three participants lived in a secure dementia unit with either vascular 
dementia (n=2) or Alzheimer’s disease (n=1). The remaining participant resided in a low care 
area and had mild to moderate dementia, as reflected by her MMSE score.  
Insert Table 3. 
 
3.1 Feasibility Indicators 
3.1.1 Acceptability 
Both family and care staff accepted the use of DreamPad™, and they welcomed the trial of 
DreamPad™ as they wanted to improve opportunities for participants to enhance sleep and 
reduce wandering and agitation. Family and care staff found the cost of DreamPad™ (i.e. $530 
inclusive of the MP3 player) to be of a ‘fair price’ and could be covered by either the family 
or nursing home if it was found to be effective in improving sleep, wandering and agitated 
behaviors. No concerns were reported on the use of DreamPad™ at the end of the intervention 
period. While the use of DreamPad™ was reported to be ‘pretty easy and straightforward’, 
perceptions of the use of DreamPad™, including SenseWear®, by residents and the associated 
change in their sleep, wandering and agitated behaviors were mixed (refer to Table 4). 
Generally, care staff interviewed believed that the effects of DreamPad™ would vary among 
residents and that the device was less likely suited for those highly agitated or with severe 
cognitive impairment.  
Insert Table 4. 
 
3.1.2 Efficacy 
Paired sample t-test revealed no significant difference in CMAI-SF scores (p=.47) before 
(M=28.3; SD=2.9) and after the intervention (M=31.3; SD=8.3). Table 3 reflects the CMAI-SF 
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scores for each participant pre- and post DreamPad™ intervention at baseline and across the 
4-week intervention period. Additionally, on average, participants only wore SenseWear® for 
a total of 74.1hrs (SD=28.5), ranging from 34.3 to 96.1 hours, out of a maximum of 120 hours. 
This reflects that the total average wear adherence of SenseWear® by participants was 61.7% 
(SD=23.7). A further detailed breakdown of each participant’s use of Dreampad™ and 
SenseWear® is reported in Table 3. The significantly large amount of missing data (i.e. step 
count and sleep type and duration), due to non-wear adherence of SenseWear® by all 
participants, as reported in Tables 3 and 4, did not permit any meaningful analysis or 
interpretation of the recorded data. Therefore, participants’ step count trends over 24 hours, as 
recorded by SenseWear®, during baseline and the 4-week intervention period are presented in 
Figure 3. Similarly, participants’ sleep type and duration trends during baseline and the 4-week 
intervention period are presented in Figure 4. Trends of step count and sleep type and duration 
are varied between participants.  
Insert Figures 3 & 4.  
 
3.1.3 Implementation & Practicality 
Basic training, together with an instruction and troubleshooting guide, were provided for care 
staff in the operation of the Dreampad™ and the MP3 player as well as the charging of the 
MP3 player (i.e. 10 hours playtime per full charge) and SenseWear® (i.e. 4 days of recording 
per full charge). There were no reported challenges during training or difficulties in the 
operation and charging of Dreampad™, the MP3 player and SenseWear® during the 
intervention period.  
 
Overall, participants recorded an average usage adherence of Dreampad™ of 82.1% (SD=8.2) 
usage of Dreampad™, ranging from 21 to 25 days use out of 28 days (M=23; SD=2.3), as 
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indicated on the intervention checklist. Reasons for non-usage of Dreampad™ by participants 
as indicated on the intervention checklist included irritation with the sound/music (n=5), not 
sleeping due to being unwell (n=1) and unable to locate the MP3 player (n=1). It was noted 
that 65% of Dreampad™ usage omissions (i.e. 13 out of 20 days across all participants), 
reflected on the intervention checklist, were not accompanied by an explanation. It was unclear 
if these omissions were due to usage refusal by participants, usage oversight by care staff or an 
uncharged MP3 player.  
 
4. Discussion 
This study aimed to assess the feasibility of using Dreampad™ to improve sleep, wandering 
and agitated behaviors in people living with dementia in RACFs. Findings of our study found 
that family and care staff deemed Dreampad™ to be acceptable for use with people living with 
dementia and they may successfully implement Dreampad™ for people with dementia in 
RACFs. However, there is no established support that sleep, wandering, and agitated behaviors 
of people living with dementia are improved via the use of  Dreampad™.  
 
In this study, the use and cost of Dreampad™ were found to be acceptable to family and care 
staff, and it was found to be generally feasible for use by people living with dementia. The 
overall average usage adherence of Dreampad™ by people living with dementia was relatively 
high (i.e. over 80%). Although two out of the four people living with dementia who took part 
in this study did, at times, express their irritation with the music heard through their pillow, 
they continued with the use of Dreampad™ during the intervention. Nevertheless, this may 
suggest the possibility of some people living with dementia who may resist the use of 
DreamPad™. A larger sample study will help us to understand this issue.  
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This feasibility study did not demonstrate evidence to support the use of DreamPad™ to 
improve sleep in people living with dementia. This preliminary result is not in concordance 
with the promising effect on sleep found in children with ADHD; people aged 25 to 65 year 
with self-reported poor sleep (26), and patients with insomnia (27). Furthermore, the influence 
of DreamPad™ on behaviors of agitation and wandering in people with dementia remains 
unclear due to the mixed results found in this study. These outcomes may be, in part, be 
explained by the intervention and data collection processes as well as the measurements used 
in this study.  
 
Several limitations need to be considered when reading the efficacy results from this feasibility 
study. First, challenges were experienced with the use of SenseWear® to assess wandering (i.e. 
step count) as well as sleep type and duration of participants in this study. Similar to other 
studies involving people living with dementia (32, 33) where some did not tolerate wearing 
SenseWear®, participants in this study exhibit similar responses where they either refused to 
wear or removed the device with reported agitation in one participant by care staff. This is 
reflected by the poor overall average wear adherence of SenseWear® by participants (i.e. slight 
over 60%). Consequently, data on step count and sleep type and duration were either 
incomplete or missing, and it proscribes any meaningful analysis or interpretation of the limited 
data captured via SenseWear®. Additionally, there were concerns with the reliability of the 
recorded data. For example, SenseWear® has been shown to under- and over-estimate step 
count (36). There are concerns about the adequacy of capturing data over 24 hours per week as 
was undertaken in this feasibility study due to resource constraints when a minimum recording 
of 72 hours is recommended (37, 38). Therefore, the promise of sleep improvement, as well as 
reduction in wandering and agitation when using Dreampad™, could not be robustly 
ascertained. It is acknowledged that wearable activity-focused devices, such as SenseWear®, 
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have distinct benefits in providing an objective measure of physical activity (e.g. step count 
relating to wandering) as well as sleep type and duration of individuals. However, results from 
this feasibility study and other earlier studies (32, 33) serve to identify some of the existing 
issues of wearable activity-focused devices when used with people living with dementia. Future 
study may need to consider (a) the use of other actigraphy, with regards to wear adherence as 
well as modifications to the comfort, size, placement, and tolerability of wearable activity-
focused technologies, or (b) the possibility of polysomnography to assess sleep over a 
minimum 3-day aggregate.  
 
Second, while usage adherence of Dreampad™ by participants in this feasibility study was 
relatively high, observed agitation when using Dreampad™ was reported in some participants. 
Future larger scale studies can provide insight into the extent of this issue for people living 
with dementia and whether Dreampad™ will further intensify agitation for those who are 
already moderately to highly agitated or with severe cognitive impairment. Third, the role of 
care staff in the usage adherence of Dreampad™ by people living with dementia, particularly 
for those who refused Dreampad™ together with the frequency and associated reasons need to 
be documented in future studies. Lastly, medications taken by participants may have influenced 
their sleep and behaviours. The lack of a medication audit did not permit any further 
investigation of the influence of medications on the effects of the Dreampad™ intervention, 
and this should be considered in future studies.  
 
Overall, the study limitations include (a) the small sample size; (b) poor wear adherence of the 
SenseWear® device by participants leading to significant missing or incomplete data; (c) the 
accuracy of step count recordings using SenseWear®; (d) the adequacy of using SenseWear® 
and only for 24 hours per week; (e) a lack of insight into what participants were doing over the 
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24 hours when the data was objectively assessed as well as during the intervention period, for 
example, participation in exercises and activities or being unwell and recuperating in bed can 
skew the data captured; (f) the influence of medications; and (g) possible inconsistent or 
irregular use of Dreampad™ during the intervention period, which may be possibly due to care 




Quality sleep is essential for health and wellbeing, and when individuals do not get adequate 
sleep, this can result in agitation and restlessness. To improve the quality of life for people 
living with dementia and their carers, safe, effective and acceptable strategies to improve sleep 
for people living with dementia are needed. This study assessed the feasibility of a new 
technological option (i.e. Dreampad™) on sleep and behaviors of agitation and wandering in 
people living with dementia that may indirectly improve outcomes for their carers.  
 
The use and cost of Dreampad™ appear acceptable to family and care staff. The device is also 
feasible for use by people living with dementia and can potentially be incorporated into daily 
use if its efficacy is established. Study outcomes have yet to demonstrate any support for 
Dreampad™ as a promising non-pharmacological intervention to improve sleep or reduce 
behaviors of agitation and wandering in people living with dementia due to intervention and 
data collection processes as well as the limitations of the measurements reported in this 
feasibility study. There continue to be challenges in using wearable actigraph technologies with 
people living dementia. Attention should be placed on the role of care staff in the consistent 
and regular use of Dreampad™ as well as data collection, including the wear adherence of 
activity-focused devices in future research endeavors. This feasibility study can be used to 
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guide a more rigorous study of Dreampad™ in people living with dementia to improve their 
sleep and behaviors of agitation and wandering. 
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Table 1. Feasibility framework (focus areas, questions, and data sources) 
Focus areas Questions Data sources 
Acceptability Is Dreampad™ deemed to be suitable for 
use by participants in residential aged care 
facilities? 
• Interviews with family & 
staff 
• Research team 
observation notes & 
reflections 
Efficacy Does Dreampad™ show promise of 
improving sleep, wandering and agitated 
behaviors in participants? 
• SenseWear® 
• Cohen-Mansfield 
Agitation Inventory – 
Short Form 
Implementation, 
and practicality  
Can Dreampad™ be successfully 
implemented with participants?  
 
• Intervention checklist 
• Research team 






Table 2. SenseWear® and Dreampad™ usage checklist 
Participant ID: _______________    
Completed by: ________________    
Start Date: ____________ 
(SenseWear® [SW] to be worn for 24hrs per week – Tues 12pm to Wed 12pm) 
Week 1 
Date: 
Mon Dreampad™ used: Yes/No 
Time on: 
Notes: 
Tues SenseWear® used: Yes/No 
Time on: 




Wed SenseWear® (SW) removed: 
Yes/No 
Time off: 
Data downloaded and SW charged:                
Yes/No 
Dreampad™ used: Yes/No 
Time on: 
Notes: 
Thurs Dreampad™ used: Yes/No 
Time on: 
Notes: 
Fri Dreampad™ used: Yes/No 
Time on: 
Notes: 
Sat Dreampad™ used: Yes/No 
Time on: 
Notes: 















Age (years) 99 87 82 91 
Gender Female Male Male Female 
Time in facility (years) 4 to 6 1 to 3 1 to 3 1 to 3 








MMSE 21 9 7 0 
Dreampad™ Usage  
(days out of 28) 
21 21 25 25 
SenseWear® Usage 
(hours)* 
18.6 14.5 19.2 6.9 
   Baseline 15 14.3 23.8 22.9 
   Week 1 23.9 23.8 19.4 2.4 
   Week 2 13.2 23.7 16.8 1.4 
   Week 3 17.1 10.9 23.8 1.7 
   Week 4 24 0 12.3 5.9 
CMAI-SF     
Pre 25 28 32 28 
Post 20 40 32 33 
*Average 24 hours wear time across 5 weeks (i.e. baseline and weeks 1 to 4) 
^ Participants A, B & D were from facility one 
# Participant C was from facility two 
  
Table 4. Summary of family and care staff perceived used of DreamPad™ and SenseWear® and change in sleep, wandering and agitated 
 DreamPad™ use SenseWear® use Sleep, wandering & agitation 
Participant A 
(PA) 
• PA found DreamPad™ 
“annoying” and 
“disturbing” and on some 
occasions “took the MP3 
player out of her pillow”. 
• PA wore SenseWear® as 
scheduled but did attempt to 
remove it over the 24-hour 
wearing period – leading to 
missing data on sleep & step 
counts.  
Care staff reported: 
• noticeable improvement in PA’s night-time sleep and 
a reduction in her behaviors of wandering and 
agitation (as reflected in CMAI-SF scores and 
SenseWear® data trends). 
• PA slept well on the nights DreamPad™ was used. 
• PA was observed to be awake and sitting on her bed 
at night when DreamPad™ was not used and looking 




• PB complained about 
DreamPad™ and “hearing 
noises through his pillow” 
when in bed. 
• The use of SenseWear® 
“exacerbated his agitation” 
leading to PB’s refusal to 
wear it – leading to missing 
data on sleep & step counts 
particularly in Week 4.  
Care staff reported: 
• no observable differences in PA’s sleep, wandering 
or agitation (as reflected in CMAI-SF scores and 
SenseWear® data trends). 
Participant C 
(PC) 
• PC was unwell with a cold 
prior to the start of the 
intervention which affected 
his mobility, sleep and use 
of DreamPad™ at baseline 
and in Week 1 (i.e. constant 
coughing fits disrupting 
sleep) – subsequent sleep 
improvement trend may be 
due to poor sleep at baseline 
due to sickness. 
• PC wore SenseWear® as 
scheduled but did attempt to 
remove it at times – leading 
to missing data on sleep & 
step counts. 
Wife reported: 
• no observable differences in wandering or agitation 




• No problem reported with 
PD’s use of DreamPad™. 
• PD often refused to wear or 
removed the SenseWear® 
device – leading to missing 
data on sleep & step counts. 
Care staff reported: 
• no observable differences in PA’s sleep, wandering 
or agitation (as reflected in CMAI-SF scores and 








Figure 2. SenseWear® 
 
 
Figure 3. Participants’ step count over 24 hours during baseline and weeks 1 to 4 
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